Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Bluejay Diagnostics Inc(BJDX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BJDX
09/25/2026: BJDX (1-star) is currently NOT-A-BUY. Pass it for now.
Bluejay Diagnostics is a speculative, early-stage healthcare company focused on developing the Symphony platform, a point-of-care diagnostic system designed for rapid testing. While the company offers a lean, technology-driven approach that addresses the clinical need for quick diagnostic results, it faces significant risks common to pre-commercial firms, including limited revenue and the requirement for consistent capital raises. Its primary opportunity lies in securing regulatory approval and establishing a presence in decentralized clinical markets. Investors should monitor FDA filing progress and potential commercial partnerships. Given the volatility, this stock is typically best suited for investors with a high risk tolerance.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play dependent on successful product commercialization. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find interest during periods of clinical or regulatory news flow. |
| Value investor | Weak fit | The company lacks current earnings or traditional value metrics to support a value-based investment thesis. |
| Dividend investor | Weak fit | The company is in an early-stage development phase and does not pay dividends. |
| Low-risk investor | Weak fit | The stock exhibits significant volatility and business risk associated with early-stage medical technology. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a micro-cap stock, price swings can be extreme due to market sentiment and low liquidity. |
| Valuation risk | High | Valuation is speculative and heavily dependent on the future success of unproven products. |
| Competition risk (diagnostics giants) | High | Dominant competitors have more resources and deeper market penetration. |
| Business quality | Medium | The business is at a nascent stage with unproven commercial scalability. |
| Dividend income | Low / none | No income potential exists for dividend-focused investors. |
| Execution risk | High | The transition from development to commercial success is fraught with regulatory and manufacturing challenges. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -43.38% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.95M USD | Price to earnings Ratio - | 1Y Target Price 256 |
Price to earnings Ratio - | 1Y Target Price 256 | ||
Volume (30-day avg) 2.3M shares | Beta 0.91 | 52 Weeks Range 0.80 - 16.68 | Updated Date 09/27/2026 |
52 Weeks Range 0.80 - 16.68 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Point-of-Care Diagnostics | The future sale of Symphony diagnostic systems and recurring revenue from proprietary test cartridges. | Revenue will depend entirely on getting products approved and selling them to hospitals. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8.52M | Price to Sales(TTM) 54.99 |
Enterprise Value -8.52M | Price to Sales(TTM) 54.99 | ||
Enterprise Value to Revenue 5.67 | Enterprise Value to EBITDA -0.1 | Shares Outstanding 1.03M | Shares Floating 4.38M |
Shares Outstanding 1.03M | Shares Floating 4.38M | ||
Percent Insiders 2.03 | Percent Institutions 9.79 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Bluejay Diagnostics Inc
Exchange NASDAQ | Headquarters Acton, MA, United States | ||
IPO Launch date 2021-11-10 | Principal Financial, Accounting & Executive Officer, President, CEO and Director Mr. Indranil Dey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://bluejaydx.com |
Full time employees 6 | Website https://bluejaydx.com | ||
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.